---
title: 'Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and
  high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD'
date: '2023-09-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37715270/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230916180929&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Currently, there is no commonly accepted standard for salvage
  chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic
  burden, achieve the best possible remission, and perform a hemopoietic stem-cell
  transplantation. Thus, in patients with FLT3-ITD mutation, the comparison of quizartinib
  with intensive salvage therapy versus chemotherapy alone appears as a logical consequence
  in terms of efficacy and ...'
disable_comments: true
---
CONCLUSION: Currently, there is no commonly accepted standard for salvage chemotherapy treatment. The objective of the salvage therapy is to reduce leukemic burden, achieve the best possible remission, and perform a hemopoietic stem-cell transplantation. Thus, in patients with FLT3-ITD mutation, the comparison of quizartinib with intensive salvage therapy versus chemotherapy alone appears as a logical consequence in terms of efficacy and ...